Future COVID-19 vaccine possibly priced under €10

Future COVID-19 vaccine possibly priced under €10

Sanofi is considering releasing an active pharmaceutical ingredients company

A few days after they announced that their joint vaccine would undergo human clinical trials, Sanofi and GSK started the week with additional news regarding the vaccine.

Oliver Bogillot, Sanofi’s French CEO, announced that the vaccine's price would be €10 or less. Despite the announcement, he iterated the fact that the final price hadn't been set yet.

Besides the price, the Sanofi plans to list its active pharmaceutical ingredients (API) company publicly. The initial public offering is scheduled to happen in the following months, and the new business could be valued at up to €2billion.

It is the embodiment of a plan touted in February, through which Sanofi will create a standalone company by reuniting under the same roof its commercial and development activities and the power of its six European production sites.

According to Sanofi, the move would balance the industry's reliance on Asia for ingredients, which lately has been disrupted by the pandemic. The drugmaker said that it is taking into consideration a 2022 Euronext Paris listing. If it does it, the new API would be the second-largest in the world after the Swiss Lonza.

Following the news, Sanofi stock price gained 2%.

If you are interested in trading companies that are in the race of developing a COVID-19 vaccine, check-out our COVID Blend!

Sources: marketwatch.com, finance.yahoo.com

La información presentada aquí está preparada por CAPEX.com y no pretende constituir un asesoramiento de inversión. La información aquí se proporciona como una comunicación general de marketing con propósitos solo de información, y como tal, no se han preparado de acuerdo con los requisitos legales diseñados para promover la independencia de un estudio de inversión, y no está sujeto a ninguna prohibición para hacer frente con antelación a la diseminación de los análisis de inversión.

Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.

Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. El rendimiento pasado no es un indicador confiable de resultados futuros.